Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays

Argonde C. van Harten, Heather J. Wiste, Stephen D. Weigand, Michelle M. Mielke, Walter K. Kremers, Udo Eichenlaub, Roy B. Dyer, Alicia Algeciras-Schimnich, David S. Knopman, Clifford R. Jack, Ronald C. Petersen

Research output: Contribution to journalArticleAcademicpeer-review

24 Citations (Scopus)

Abstract

Introduction: We aimed to provide cut points for the automated Elecsys Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers. Methods: Cut points for Elecsys amyloid beta 42 (Aβ42), total tau (t-tau), hyperphosphorylated tau (p-tau), and t-tau/Aβ42 and p-tau/Aβ42 ratios were evaluated in Mayo Clinic Study of Aging (n = 804) and Mayo Clinic Alzheimer's Disease Research Center (n = 70) participants. Results: The t-tau/Aβ42 and p-tau/Aβ42 ratios had a higher percent agreement with normal/abnormal amyloid positron emission tomography (PET) than the individual CSF markers. Reciever Operating Characteristic (ROC)-based cut points were 0.26 (0.24–0.27) for t-tau/Aβ42 and 0.023 (0.020–0.025) for p-tau/Aβ42. Ratio cut points derived from other cohorts performed as well in our cohort as our own did. Individual biomarkers had worse diagnostic properties and more variable results in terms of positive and negative percent agreement (PPA and NPA). Conclusion: CSF t-tau/Aβ42 and p-tau/Aβ42 ratios are very robust indicators of AD. For individual biomarkers, the intended use should determine which cut point is chosen.
Original languageEnglish
JournalAlzheimer's and Dementia
Early online date2021
DOIs
Publication statusE-pub ahead of print - 2021

Keywords

  • Alzheimer's disease
  • CSF
  • biomarkers
  • cut point

Cite this